Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 12/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075465 | 0.82 | ALDH1A1 (0.35) | KDM4ENPC1L3MBTL1ALDH1A1IDO1 | |
| SCHEMBL5016075 | 0.75 | GRM2 (0.56) | IDO1 | |
| SCHEMBL19911468 | 0.74 | ALDH1A1 (0.44) | KDM4ENPC1L3MBTL1ALDH1A1HTT | |
| SCHEMBL10882378 | 0.74 | NPC1 (0.50) | KDM4ENPC1L3MBTL1ALDH1A1HTT | |
| SCHEMBL10825780 | 0.71 | GRM2 (0.46) | KDM4ENPC1L3MBTL1ALDH1A1HTT | |
| SCHEMBL2903449 | 0.71 | KCNMA1 (0.45) | KDM4ENPC1L3MBTL1ALDH1A1IDO1 | |
| SCHEMBL19915701 | 0.65 | NT5E (0.38) | L3MBTL1ALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL165333 | 0.64 | SMN1; SMN2 (0.71) | KDM4ENPC1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL438499 | 0.64 | IDO1 (0.76) | IDO1 | |
| SCHEMBL5014369 | 0.64 | IDO1 (0.41) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| CN-101107000-A | 3,6-bicyclolides | ENANTA PHARM INC (US) | 2008-01-16 | — | — | CN | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | KDM4E 2778/4885NPC1 299/4885L3MBTL1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.